Heikki Lanckriet Buys 2,400 Shares of 4basebio PLC (LON:4BB) Stock

4basebio PLC (LON:4BB - Get Free Report) insider Heikki Lanckriet purchased 2,400 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The stock was acquired at an average cost of GBX 1,205 ($15.40) per share, with a total value of £28,920 ($36,953.74).

4basebio Price Performance

Shares of 4basebio stock traded down GBX 15 ($0.19) during trading on Wednesday, hitting GBX 1,165 ($14.89). The stock had a trading volume of 608 shares, compared to its average volume of 946. The business has a fifty day moving average of GBX 1,141.21 and a two-hundred day moving average of GBX 1,225.74. 4basebio PLC has a fifty-two week low of GBX 940 ($12.01) and a fifty-two week high of GBX 1,820 ($23.26). The firm has a market cap of £149.24 million, a P/E ratio of -1,493.59 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada reaffirmed an "outperform" rating and issued a GBX 1,600 ($20.44) target price on shares of 4basebio in a research report on Thursday, March 13th.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.